



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

28 July 2015

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date**

Important notices

- NIMH Clinical Research Policies and Guidance ([NOT-MH-15-025](#))
- ASSIST Now an Option for Institutional Training and Career Development (Ts and K12), Other Training Grants (Ds) ([NOT-OD-15-126](#))
- Preliminary Guidance Related to Informed Consent for Research on Dried Blood Spots Obtained Through Newborn Screening ([NOT-OD-15-127](#))
- Request for Information (RFI) on the Action Plan for Lupus Research ([NOT-AR-15-018](#))
- Notice to Emphasize the Requirement for Certification Letter to Verify Eligibility of the Applicant for PAR-15-053 "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)" ([NOT-CA-15-025](#))
- Notice of Participation of the Eunice Kennedy Shriver National Institute of Child Health and Human Development in PAR-15-274 Ethical Issues in Research on HIV/AIDS and its Co-Morbidities (R01)" ([NOT-HD-15-025](#))
- Notice of Participation of the Eunice Kennedy Shriver National Institute of Child Health and Human Development in PAR-15-275 Ethical Issues in Research on HIV/AIDS and its Co-Morbidities (R21)" ([NOT-HD-15-026](#))
- Notice of Participation of the Eunice Kennedy Shriver National Institute of Child Health and Human Development in PA-15-271 "Understanding HIV Persistence in Infants (R01)" ([NOT-HD-15-027](#))
- Notice of New Application Package Required for PAR-15-292 "Emerging Global Leader Award (K43)" ([NOT-TW-15-003](#))

1. Title: GenitoUrinary Development Molecular Anatomy Project (GUDMAP) - Atlas Projects

Letter of Intent due date: October 9, 2015

Hyperlink: [\(RFA-DK-15-014\)](#)

Type: UO1

Application Due Date: November 9, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Purpose: This FOA requests applications for GUDMAP Atlas Projects to generate data for the GUDMAP database. The scope of Atlas projects is limited to either human or murine studies. The interrogation of human tissue is limited to normal developing tissues of the kidney or lower urinary tract. Murine studies may include the molecular anatomy of the innervation and vasculature of the kidney, as well as lower urinary tract organs. Furthermore, murine studies may include the interrogation of well-chosen sets of murine developmental diseases or defects of the kidney and lower urinary tract. The GUDMAP Atlas Projects will be part of the GUDMAP consortium which has established a molecular anatomy atlas of the developing murine kidney and the lower urinary tract. Proposed human studies should take advantage of the GUDMAP murine atlas and be designed to inform the generation of new murine models of human disease or developmental defects. Murine studies should fill in knowledge gaps in the current atlas. GUDMAP is expected to be a continuing resource for the genitourinary research communities and its long-term objectives are to establish a comprehensive understanding of urinary tract tissue development and maturation to inform the study of tissue maturation and aging, organ dysgenesis and disease, and ultimately organ repair and regeneration. Two separate FOAs seek applications for Human Tissue Core (RFA-DK-15-016) and one Database Website Project (e.g., data coordinating center) (RFA-DK-15-015).

Budget: Direct costs are expected to be in the range of \$100,000 to \$200,000 per year. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

2. Title: Supplements to Support Evaluation of the NCI Cancer Genomics Cloud Pilots (Admin Supp)

Letter of Intent due date: N/A

Hyperlink: [\(PA-15-305\)](#)

Type:

Application Due Date: October 18, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Purpose: The purpose of this FOA is to support projects that will incorporate the use of one or more of the NCI Cancer Genomics Cloud Pilots into ongoing research activities. The use of an infrastructure in which large scale genomic data is co-located with computational resources and analysis tools is expected to lead to increased research efficiency and broader access to tools and data for cancer researchers, an important priority for the NCI. The activities and outcomes of projects funded through these supplements will help inform NCI's future plans for providing a computational infrastructure for genomics data.

Budget: Application budgets are limited to \$40,000 in direct costs and must reflect the actual needs of the proposed project. Direct Costs may not exceed Parent Award Direct Costs. The project and budget periods must be within the currently approved project period for the existing parent award and the work must be completed no later than September 30, 2016.

3. Title: Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival**Letter of Intent due date:** N/A**Hyperlink:** [\(PA-15-311\)](#)
[\(PA-15-310\)](#)**Type:** R01
R21

Application Due Date: Standard dates apply RO1: 5 Feb; 5 Jun; 5 Oct by 5:00 PM local time of applicant organization. Standard dates apply R21: 16 Feb; 16 Jun; 16 Oct by 5:00 PM local time of applicant organization. Aids Dates 7 Jan; 7 May; 7 Sep by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Expiry date:** September 8, 2018

Purpose: This FOA encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will require transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.

Budget: R21- The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **RO1-** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Title: Lymphatics in Health and Disease in the Digestive System, Kidney, and Urinary Tract**Letter of Intent due date:** N/A**Hyperlink:** [\(PAR-15-306\)](#)**Type:** R01

Application Due Date: Standard dates apply RO1: 5 Feb; 5 Jun; 5 Oct by 5:00 PM local time of applicant organization. Aids Dates 7 Jan; 7 May; 7 Sep by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Expiry date:** September 8, 2018

Purpose: This FOA is to encourage Research Project Grant (R01) applications for research into aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system, kidney, and urinary tract organs. However, studies with the major focus on immune mechanisms are not encouraged. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in these organs/systems, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest.

Budget: Application budgets are limited to \$250,000 in direct costs per year exclusive of any consortium F&A costs. The scope of the proposed project should determine the project period. The maximum period is 5 years.

5. Title: Translational Studies on Adducts for Cancer Risk Identification and Prevention**Letter of Intent due date:** October 23, 2015**Hyperlink:** [\(PAR-15-307\)](#)**Type:** U01

Application Due Date: November 23, 2015; July 11, 2016, November 22, 2016; July 11, 2017, November 21, 2017; July 11, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Expiry date:** July 12, 2018

Purpose: This FOA encourages clinically-relevant translational/epidemiological research projects focused on the use of adducts to cellular macromolecules, as indicators of exposures to cancer risk factors in human populations and subgroups. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The projects are expected to be based on comprehensive use of human biospecimens for which detailed medical data are available (e.g., biospecimens from the NCI-supported cohort studies). The main emphasis of this FOA is on advancing the area of cancer detection, cancer prevention, and assessing cancer risks in human populations and subgroups. Nonetheless, studies evaluating the potential roles of adducts in cancer etiology for gene-environment interaction research may also be appropriate provided that such projects are based on appropriate sets of human biospecimens (such as specimens from cohorts studies supported by NIH).

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period may not exceed 5 years.

6. Title: Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention**Letter of Intent due date:** October 23, 2015**Hyperlink:** [\(PAR-15-308\)](#)
[\(PAR-15-309\)](#)**Type:** R01
R21

Application Due Date: November 23, 2015; July 11, 2016, November 22, 2016; July 11, 2017, November 21, 2017; July 11, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Expiry date:** July 12, 2018

Purpose: This FOA encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.

Budget: R21: Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year. **RO1:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period may not exceed 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Dr Christa de Vries* • Tel: 9838 • Email: cdevries@sun.ac.za